This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| paclitaxel | |
|---|---|
| Name | Paclitaxel |
| Tradename | Taxol, Abraxane, others |
| Routes of administration | Intravenous |
| Legal status | Prescription only |
| CAS number | 33069-62-4 |
paclitaxel
Paclitaxel is a chemotherapeutic agent used to treat multiple neoplastic conditions by stabilizing microtubules. It is administered intravenously and marketed under trade names including Taxol and Abraxane; regulatory approvals and guideline recommendations from agencies such as the United States Food and Drug Administration, European Medicines Agency, and national oncology groups have shaped its clinical use. Development, supply, and patent disputes involved institutions like Bristol-Myers Squibb, National Cancer Institute, and universities in United States and Canada.
Paclitaxel is indicated for treatment of solid tumors including ovarian cancer, breast cancer, non-small cell lung cancer, and Kaposi sarcoma with clinical practice guidance from organizations such as the National Comprehensive Cancer Network, American Society of Clinical Oncology, and European Society for Medical Oncology. In ovarian carcinoma, paclitaxel combined with platinum agents has been evaluated in trials led by groups like the Gynecologic Oncology Group and Cancer and Leukemia Group B; in breast cancer, adjuvant and metastatic settings were studied by cooperative groups including NSABP and EORTC. For non-small cell lung carcinoma, combinations with carboplatin were assessed in randomized studies sponsored by entities such as SWOG and RTOG. Off-label and investigational uses have been explored in clinical trials registered at institutions like the National Institutes of Health and cancer centers such as Memorial Sloan Kettering Cancer Center.
Paclitaxel exhibits pharmacokinetics characterized by large distribution volumes and nonlinear elimination described in pharmacology reviews from organizations like the Pharmaceutical Research and Manufacturers of America, with metabolism principally by cytochrome P450 isoenzymes CYP2C8 and CYP3A4 documented in publications from laboratories at Harvard Medical School and University of California, San Francisco. Drug–drug interactions with agents such as ritonavir, ketoconazole, and rifampin were evaluated in clinical pharmacology studies at centers including Mayo Clinic and Johns Hopkins Hospital. Therapeutic drug monitoring and dose adjustments are informed by research from academic hospitals like Massachusetts General Hospital and regulatory pharmacology committees in United Kingdom and Canada.
Paclitaxel is a diterpenoid compound originally isolated from the bark of the Pacific yew, Taxus brevifolia, in a botanical collection led by scientists at the United States Department of Agriculture and Research Triangle Institute. Chemical structure elucidation involved spectroscopic work by laboratories at Stanford University and University of California, Berkeley, with X-ray crystallography contributions from researchers associated with Bell Labs and crystallographers at Cambridge University. Natural sources include several Taxus species, and semisynthetic precursors were developed from 10-deacetylbaccatin III found in European yew species studied by botanists at Kew Gardens and chemists at University of Innsbruck.
Initial commercial production relied on extraction from yew bark under contracts with companies such as Bristol-Myers Squibb and suppliers coordinated with forestry services in Pacific Northwest and agencies like the US Forest Service. Semisynthetic production using precursors from cultivated Taxus species was scaled by manufacturers including Baxter International and captured in technology transfer with universities like University of British Columbia. Formulation innovations include albumin-bound nanoparticle formulations developed by researchers at Abraxis Bioscience and liposomal approaches explored at institutions such as Columbia University and University of Michigan.
Common toxicities reported in pivotal trials and safety databases managed by agencies such as the FDA and Health Canada include neutropenia, peripheral neuropathy, alopecia, and hypersensitivity reactions with premedication strategies developed in guidelines from ASCO and ESMO. Long-term effects such as chronic neuropathy and cardiotoxicity were evaluated in survivorship studies at centers like Dana-Farber Cancer Institute and St. Jude Children's Research Hospital. Occupational and environmental considerations for handling were addressed by regulatory bodies including Occupational Safety and Health Administration and hospital pharmacy services at institutions like Cleveland Clinic.
Paclitaxel stabilizes microtubule assemblies by binding to β-tubulin within the microtubule lumen, thereby inhibiting mitotic spindle dynamics as characterized in basic science research from laboratories at Cold Spring Harbor Laboratory and Max Planck Institute for Molecular Cell Biology and Genetics. Structural biology studies using cryo-electron microscopy and NMR spectroscopy were reported by groups at MIT and ETH Zurich, elucidating interactions pertinent to resistance mechanisms also investigated by research teams at Fred Hutchinson Cancer Research Center and Sloan Kettering Institute.
Discovery and development involved collaborative programs between the National Cancer Institute, academic researchers such as those at University of California, and industry partners including Bristol-Myers Squibb; landmark publications appeared in journals affiliated with societies like the American Association for Cancer Research and New England Journal of Medicine. The path from natural product isolation to clinical approval entailed ecological, patent, and supply controversies engaging groups such as the World Wildlife Fund and governmental agencies in United States and Canada, with subsequent generics and biosimilar developments by pharmaceutical firms in India, China, and Europe.
Category:Chemotherapeutic agents